Hikma Expands Its Genectables Business Via Acquisition

BMI View: We believe Jordanian drugmaker Hikma Pharmaceuticals' expansion of its genectables business to be a prudent strategy. Drugmakers can charge higher prices for injectable pharmaceuticals than for oral drugs and can generally realise higher profit margins. Furthermore, genectables are a high-growth sub-sector of the pharmaceutical industry, valued at US$10-12bn in 2009 by primary market research firm IMS Health.

To read the full article, please choose one of the following options: